Clinical trials: Supportive Therapy
Metastatic Colorectal Cancer
Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer
The purpose of this study is to evaluate the benefit of panitumumab in addition to best supportive care compared to best supportive care alone in patients with chemorefractory wild-type KRAS (Kirsten rat sarcoma viral oncogene…
- Trial name
- NCT01412957
- Testing
- Best Supportive Care (BSC), Panitumumab
- Where
- 78 sites in Brazil, Canada and 14 more
- Volunteers
- 377 people
- Sponsor
- Amgen
Hepatocellular Carcinoma (HCC)
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
This is a randomized, double-blind, multicenter, Phase 2 study to evaluate the efficacy and safety of ABSK-011 plus BSC versus placebo plus BSC in advanced or unresectable hepatocellular carcinoma (HCC) patients with FGF19…
- Trial name
- NCT07327034
- Testing
- ABSK-011+BSC
- Where
- 51 sites in China
- Volunteers
- 141 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Emotional Adjustment, Mood Disturbance
Digital Health for Caregivers Emotional and Self-management Support
This feasibility study builds upon mental health and technology acceptance theoretical frameworks. It seeks to examine potentials of a novel mobile Health (mHealth) solution based on emotional and behavioral change techniques, to…
- Trial name
- CARING (NCT04812665)
- Testing
- mHealth solution based on emotional and behavioral change techniques
- Where
- Spain
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Gaucher Disease
A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velaglucerase Alfa (VPRIV) Home Infusion
The main purpose of this survey is to determine participants', caregivers', and nurses' understanding and use of educational materials (EM) on VPRIV home treatment.
- Trial name
- NCT05669729
- Volunteers
- 60 people
- Sponsor
- Takeda
Medication Non-Adherence
Effectiveness Of A Program That Includes Counseling And Patient Support On Adherence To Treatment With Lipitor
Despite extensive reports of the benefits of statins in reducing serious cardiovascular events such as stroke and heart disease in patients with elevated LDL-cholesterol, patients do not take their medicines regularly as…
- Trial name
- NCT01078285
- Testing
- No Patient Counseling, Adherence Counseling
- Where
- 3 sites in United States
- Volunteers
- 500 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Type 2 Diabetes Mellitus
A Study to Compare the Use of Diabetes Treatment Support System (BAP0527 and Blood Glucose Meter) in Addition to Daily Practice and Treatment With Daily Practice and Treatment Alone in Patients With Type 2 Diabetes Mellitus
The subjects of this study are patients with type 2 diabetes mellitus. The patients take part in dietetic therapy and exercise therapy, and also receive diabetes education to improve lifestyle habits, but since diet and exercise…
- Trial name
- NCT06156696
- Testing
- BAP0527, Blood Glucose Meter
- Where
- Japan
- Volunteers
- 248 people
- Sponsor
- Astellas Pharma Inc
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?
This clinical, prospective, randomized, multi-center study determined if the use of an insulin bolus advisor improves glycemic control as measured by a change in HbA1c in patients failing multiple daily injection/intensified…
- Trial name
- ABACUS (NCT01460446)
- Testing
- Aviva Expert blood glucose meter, Aviva Nano blood glucose meter
- Where
- 33 sites in Germany, United Kingdom
- Volunteers
- 218 people
- Sponsor
- Hoffmann-La Roche
COVID-19
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
CALAVI US will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
- Trial name
- CALAVI US (NCT04380688)
- Testing
- Acalabrutinib
- Where
- 31 sites in United States
- Volunteers
- 62 people
- Sponsor
- AstraZeneca
Colorectal Neoplasms
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard chemotherapy and biological agents.
- Trial name
- NCT02149108
- Testing
- Nintedanib (BIBF 1120), BSC
- Where
- 129 sites in United States, Argentina and 23 more
- Volunteers
- 768 people
- Sponsor
- Boehringer Ingelheim
Non-Small Cell Lung Cancer
A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer
This study will compare progression-free survival in patients with advanced non-squamous non-small cell lung cancer. Patients who do not progress following 4 cycles of induction treatment with pemetrexed and cisplatin will be…
- Trial name
- NCT00789373
- Testing
- Pemetrexed, Cisplatin, Best Supportive Care
- Where
- 68 sites in Australia, Belgium and 13 more
- Volunteers
- 939 people
- Sponsor
- Eli Lilly and Company
Pancreatic Cancer
PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen
The objectives of this multi-center, randomized, controlled trial are to evaluate the safety and efficacy of PANVAC-VF in combination with Granulocyte-macrophage colony-stimulating factor (GM-CSF) versus best supportive care or…
- Trial name
- NCT00088660
- Testing
- PANVAC™-VF
- Where
- 62 sites in United States
- Volunteers
- 250 people
- Sponsor
- Therion Biologics Corporation
Jaw, Edentulous, Poor Bone Quality
Treatment With Fixture Microthread™ in Patients With Poor Bone Quality and no Teeth in the Upper Jaw, When Using Two-Stage Surgery
The primary objective of the study is to evaluate the long-term survival rate of individual implants and prostheses when treating edentulous upper jaws of poor bone quality with Fixture MicroThread™ (Micro-Macro).
- Trial name
- NCT00748670
- Testing
- Fixture MicroThread (Micro-Macro)
- Where
- 3 sites in United States, Sweden
- Volunteers
- 23 people
- Sponsor
- Dentsply Sirona Implants and Consumables
Inoperable Stage III Non-small Cell Lung Cancer
Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer
The purpose of this study is to evaluate survival in inoperable stage III Non-small Cell Lung Cancer patients following chemo-radiotherapy followed by GV1001 vaccination plus best supportive care.
- Trial name
- LucaVax (NCT01579188)
- Testing
- GV1001, normal saline
- Volunteers
- 600 people
- Sponsor
- Kael-GemVax Co., Ltd.
Non-Hodgkin's Lymphoma
Treatment for Subjects With Non-Hodgkin's Lymphoma
This multicenter, open-label, randomized, parallel study was designed to evaluate whether a single fixed-dose subcutaneous (SC) administration of pegfilgrastim or daily administration of Filgrastim for absolute neutrophil count…
- Trial name
- NCT00117897
- Testing
- pegfilgrastim, Filgrastim
- Sponsor
- Amgen
Myelodysplastic Syndrome
The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)
Evaluation of the Efficacy and Safety of Oral Azacitidine plus Best Supportive care versus Placebo and Best Supportive care in subjects with red blood cell (RBC) transfusion-dependent anemia and thrombocytopenia due to…
- Trial name
- NCT01566695
- Testing
- Oral Azacitidine, Best Supportiv Care (BSC)
- Where
- 196 sites in United States, Australia and 21 more
- Volunteers
- 216 people
- Sponsor
- Celgene
Relapsing Multiple Sclerosis
Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients
The objective is to establish the impact of current disease modifying therapies (DMTs) and associated support services on Patient Reported Experience Measures and Patient Reported Outcomes in relation to the treatment and…
- Trial name
- NCT01601119
- Testing
- Rebif, Other: Disease modifying therapies (DMT)
- Where
- United Kingdom
- Volunteers
- 545 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Neutropenic Complications, Breast Neoplasms
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®
The study will assess the efficacy of LA-EP2006 compared to Neulasta® with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.
- Conditions
- Neutropenic Complications, Breast Neoplasms, Chemotherapy-induced Neutropenia, Chemotherapeutic Toxicity
- Trial name
- PROTECT-1 (NCT01735175)
- Testing
- LA-EP2006, Neulasta®
- Where
- 41 sites in Brazil, India and 4 more
- Volunteers
- 316 people
- Sponsor
- Sandoz
Stress Urinary Incontinence
TVT-SECUR A Pilot Study for the Treatment of Stress Urinary Incontinence
The primary objective of this study is to obtain clinical performance information on the GYNECARE TVT-SECUR* System (Tension-free Support for Incontinence) in women with stress urinary incontinence (SUI).
- Trial name
- NCT00463554
- Testing
- GYNECARE TVT-SECUR* System
- Where
- 6 sites in United States, Finland and 1 more
- Volunteers
- 72 people
- Sponsor
- Ethicon, Inc.
Gastrointestinal Stromal Tumors
Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)
A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors…
- Trial name
- GRID (NCT01271712)
- Testing
- Regorafenib (Stivarga, BAY73-4506), Best supportive care
- Where
- 57 sites in United States, Austria and 15 more
- Volunteers
- 199 people
- Sponsor
- Bayer
Short Bowel Syndrome
Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support
Part A:once weekly dosing for 4 weeks in patients with short bowel syndrome who require total parenteral nutrition; patients will complete period 1 and after a 6-10 week wash-out, they will enter period 2 (active treatment and…
- Trial name
- NCT03415594
- Testing
- FE203799 GLP-2 analogue
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- GlyPharma Therapeutics